Roche, through its Genentech subsidiary, is investing $95m in SR One-backed Constellation Pharmaceuticals as part of a partnership to develop a new breed of gene-based drugs.
Constellation Pharmaceuticals, a US-based molecular therapeutics company, signed a strategic agreement worth $95m with Genentech, a subsidiary of the Roche pharmaceutical conglomerate, on Tuesday.
Genentech and Constellation plan to launch a collaborative partnership based on Constellation’s epigenetics science, which will lead to treatments being developed to combat cancer and other serious diseases. Genentech also has the option to acquire all outstanding shares in Constellation, should it choose to do so in future.
The funding will be made up of…
